While the therapeutic strategy of using single-agent VEGF-TKIs, mTOR inhibition, MET inhibitors, and ICIs each demonstrated some activity in pRCC, these paled in comparison to that of the findings in ccRCC. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.